Ambu Valuation
Is AMBUBC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AMBUBC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AMBUBC (DKK115.45) is trading below our estimate of fair value (DKK119.11)
Significantly Below Fair Value: AMBUBC is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AMBUBC?
Key metric: As AMBUBC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is AMBUBC's PE Ratio? | |
|---|---|
| PE Ratio | 129.8x |
| Earnings | DKK 235.00m |
| Market Cap | DKK 30.50b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.6x |
| Enterprise Value/EBITDA | 39x |
| PEG Ratio | 4.6x |
Price to Earnings Ratio vs Peers
How does AMBUBC's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 30.9x | ||
SN. Smith & Nephew | 35.3x | 22.5% | UK£8.6b |
NIOX NIOX Group | 23.7x | 17.1% | UK£260.3m |
EKF EKF Diagnostics Holdings | 24.4x | n/a | UK£116.6m |
CTEC ConvaTec Group | 40.4x | 20.5% | UK£4.9b |
AMBUBC Ambu | 129.8x | 28.1% | DKK 30.5b |
Price-To-Earnings vs Peers: AMBUBC is expensive based on its Price-To-Earnings Ratio (129.8x) compared to the peer average (30.9x).
Price to Earnings Ratio vs Industry
How does AMBUBC's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: AMBUBC is expensive based on its Price-To-Earnings Ratio (129.8x) compared to the European Medical Equipment industry average (29.7x).
Price to Earnings Ratio vs Fair Ratio
What is AMBUBC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 129.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate AMBUBC's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | DKK 115.45 | DKK 126.83 +9.9% | 20.1% | DKK 160.00 | DKK 76.00 | n/a | 6 |
| Nov ’25 | DKK 129.30 | DKK 128.67 -0.5% | 18.5% | DKK 145.00 | DKK 76.00 | n/a | 6 |
| Oct ’25 | n/a | DKK 125.50 0% | 19.1% | DKK 145.00 | DKK 76.00 | n/a | 6 |
| Sep ’25 | DKK 142.23 | DKK 126.40 -11.1% | 21.9% | DKK 160.00 | DKK 76.00 | n/a | 5 |
| Aug ’25 | DKK 136.60 | DKK 117.00 -14.3% | 25.0% | DKK 138.00 | DKK 59.00 | n/a | 5 |
| Jul ’25 | n/a | DKK 117.00 0% | 25.0% | DKK 138.00 | DKK 59.00 | n/a | 5 |
| Jun ’25 | n/a | DKK 111.20 0% | 24.9% | DKK 138.00 | DKK 59.00 | n/a | 5 |
| May ’25 | n/a | DKK 107.20 0% | 26.4% | DKK 130.00 | DKK 52.00 | n/a | 5 |
| Apr ’25 | DKK 112.43 | DKK 107.20 -4.6% | 26.4% | DKK 130.00 | DKK 52.00 | n/a | 5 |
| Mar ’25 | n/a | DKK 107.20 0% | 26.4% | DKK 130.00 | DKK 52.00 | n/a | 5 |
| Feb ’25 | n/a | DKK 105.00 0% | 26.7% | DKK 130.00 | DKK 52.00 | n/a | 5 |
| Jan ’25 | n/a | DKK 85.67 0% | 26.2% | DKK 115.00 | DKK 47.00 | n/a | 6 |
| Dec ’24 | DKK 94.37 | DKK 85.67 -9.2% | 26.2% | DKK 115.00 | DKK 47.00 | n/a | 6 |
| Nov ’24 | n/a | DKK 89.40 0% | 28.2% | DKK 120.00 | DKK 53.00 | DKK 129.30 | 5 |
| Oct ’24 | n/a | DKK 95.60 0% | 25.6% | DKK 120.00 | DKK 53.00 | n/a | 5 |
| Sep ’24 | n/a | DKK 96.00 0% | 25.3% | DKK 120.00 | DKK 53.00 | DKK 142.23 | 5 |
| Aug ’24 | n/a | DKK 101.80 0% | 27.0% | DKK 135.00 | DKK 59.00 | DKK 136.60 | 5 |
| Jul ’24 | n/a | DKK 102.60 0% | 26.9% | DKK 135.00 | DKK 59.00 | n/a | 5 |
| Jun ’24 | DKK 108.60 | DKK 102.60 -5.5% | 26.9% | DKK 135.00 | DKK 59.00 | n/a | 5 |
| May ’24 | DKK 107.95 | DKK 101.60 -5.9% | 28.4% | DKK 135.00 | DKK 55.00 | n/a | 5 |
| Apr ’24 | n/a | DKK 96.25 0% | 30.8% | DKK 135.00 | DKK 55.00 | DKK 112.43 | 4 |
| Mar ’24 | n/a | DKK 104.60 0% | 30.2% | DKK 140.00 | DKK 55.00 | n/a | 5 |
| Feb ’24 | DKK 97.64 | DKK 87.80 -10.1% | 20.6% | DKK 110.00 | DKK 65.00 | n/a | 5 |
| Jan ’24 | n/a | DKK 83.40 0% | 19.5% | DKK 110.00 | DKK 65.00 | n/a | 5 |
| Dec ’23 | DKK 91.44 | DKK 83.20 -9.0% | 19.8% | DKK 110.00 | DKK 64.00 | DKK 94.37 | 5 |
| Nov ’23 | DKK 84.06 | DKK 76.50 -9.0% | 11.7% | DKK 85.00 | DKK 64.00 | n/a | 4 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Guerbet
€339.2m
Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.
0ELV
€27.00
7D
-9.8%
1Y
50.2%
Arjo
SEK 9.2b
Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.
0HQ8
SEK 33.92
7D
-4.8%
1Y
-9.6%
Fagron
€1.3b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
0HNZ
€18.06
7D
-6.1%
1Y
5.3%